NCT00249977View on ClinicalTrials.gov

Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

August 31, 2007

Study Completion Date

January 31, 2009

Conditions
Solid TumorsCancer
Interventions
DRUG

Capecitabine in Combination with Cisplatin and Irinotecan

"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."

Trial Locations (1)

87131

University of New Mexico, Albuquerque

All Listed Sponsors
lead

University of New Mexico

OTHER

NCT00249977 - Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan | Biotech Hunter | Biotech Hunter